Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11627675 | 0.79 | SLC5A1 (0.71) | LMNAHTTSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL10558859 | 0.75 | PIK3CA (0.70) | LMNAHTTSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL6201900 | 0.72 | RAB9A (0.59) | LMNAHTTSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL4291295 | 0.72 | LMNA (0.54) | LMNAHTTSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL16322177 | 0.72 | LMNA (0.77) | LMNAHTTSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL10564935 | 0.71 | LMNA (0.77) | LMNAHTTSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL17838422 | 0.71 | SMN1; SMN2 (0.57) | LMNAHTTSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL5724883 | 0.70 | RAB9A (0.68) | LMNAHTTSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL150523 | 0.70 | LMNA (0.60) | LMNAHTTSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL526194 | 0.69 | GAA (0.57) | LMNAHTTSMN1; SMN2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233818-A1 | DERIVATIVES OF 2,3-DIPHENYLCHROMENE USEFUL FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097073-A1 | DERIVATIVES OF 2,3-DIPHENYLCHROMENE USEFUL FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097073-A1 | DERIVATIVES OF 2,3-DIPHENYLCHROMENE USEFUL FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175284-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | LMNA 2688/4885HTT 4176/4885SMN1; SMN2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.